Stockscreener 앱 받기
1.65
14.51%
-0.28
시간 외 거래:
1.95
0.30
+18.18%
전일 마감가:
$1.93
열려 있는:
$1.91
하루 거래량:
496.49K
Relative Volume:
0.31
시가총액:
$6.28M
수익:
$556.00K
순이익/손실:
$-5.28M
주가수익비율:
-0.771
EPS:
-2.14
순현금흐름:
$-6.23M
1주 성능:
+23.13%
1개월 성능:
-0.60%
6개월 성능:
-52.45%
1년 성능:
-49.07%
1일 변동 폭
$1.65
$2.00
1주일 범위
$1.28
$2.28
52주 변동 폭
$1.16
$6.25
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
명칭
Cyclerion Therapeutics Inc
전화
617-621-7722
주소
301 BINNEY STREET, CAMBRIDGE, MA
CYCN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
1.65 | 7.35M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-20 | 개시 | Truist | Buy |
| 2021-09-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-03 | 개시 | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc 주식(CYCN)의 최신 뉴스
Is Cyclerion Therapeutics Inc. stock a safe buy before earningsJuly 2025 Momentum & AI Based Buy and Sell Signals - ulpravda.ru
Top Penny Stocks To Follow NowJanuary 6th - MarketBeat
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Why Cyclerion Therapeutics Inc. stock could rally in 2025Rate Hike & Real-Time Buy Zone Alerts - ulpravda.ru
Why retail investors favor Cyclerion Therapeutics Inc. stockTreasury Yields & Daily Entry Point Trade Alerts - ulpravda.ru
Top Penny Stocks To Follow Now – January 6th - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant DepressionSlideshow (NASDAQ:CYCN) 2026-01-07 - Seeking Alpha
Exciting Surge in Cyclerion: What’s Next? - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cyclerion Therapeutics Collaboration Sparks Curiosity - timothysykes.com
Cyclerion, Medsteer form strategic anesthetic technology alliance - TipRanks
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next - TechStock²
Stay updated with the stocks that are on the move in today's pre-market session. - Chartmill
Morning Market Movers: CYCN, AZI, AEVA, OS See Big Swings - RTTNews
Cyclerion (CYCN) Enters Exclusive Collaboration with Medsteer to Advance CYC-126 Clinical Trials - Intellectia AI
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Cyclerion partners with Medsteer to advance depression treatment platform By Investing.com - Investing.com Nigeria
Cyclerion Expands Partnership With Medsteer; Plans Phase 2 Trial Of CYC-126 In 2H 2026; Stock Up - Nasdaq
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket - Benzinga
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI) - Defense World
Cyclerion Therapeutics Inc. (CYCN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cyclerion announces strategic agreement with Medsteer - MarketScreener
Cyclerion Therapeutics (CYCN) Enhances Depression Treatment Prog - GuruFocus
Wondering what's happening in today's after-hours session? - Chartmill
Cyclerion partners with Medsteer to advance depression treatment platform - Investing.com India
Cyclerion Therapeutics stock soars after strategic Medsteer collaboration By Investing.com - Investing.com Nigeria
Cyclerion Therapeutics stock soars after strategic Medsteer collaboration - Investing.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Cyclerion Therapeutics, Inc. Announces Progress Toward Initiating Phase 2 Proof-Of-Concept Study for CYC-126 in Treatment-Resistant Depression - MarketScreener
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ICICI Prudential AMC Ltd (542629) Quarterly Results Are OutMonthly Performance Summary & Superior Wealth Building - bollywoodhelpline.com
Cyclerion Therapeutics Inc Stock Analysis and ForecastDividend Stability Analysis & Turn Bull Runs into Life-Changing Wealth - earlytimes.in
Critical Contrast: Cyclerion Therapeutics (NASDAQ:CYCN) versus Response Genetics (OTCMKTS:RGDXQ) - Defense World
Panjon Limited Flashes Buy Signal on Multi Timeframe ChartMoving Average Crossovers & High Return Wealth Building - bollywoodhelpline.com
Cyclerion Therapeutics Relaunches with Neuropsychiatric Focus - MSN
Will Cyclerion Therapeutics Inc. stock reach all time highs in 2025Weekly Trend Summary & Reliable Entry Point Alerts - Улправда
Should I hold or sell Cyclerion Therapeutics Inc. stock in 20252025 Geopolitical Influence & Technical Pattern Recognition Alerts - Улправда
How Cyclerion Therapeutics Inc. stock benefits from strong dollarJuly 2025 Institutional & Daily Risk Controlled Trade Plans - Улправда
Rate Hike: Will Cyclerion Therapeutics Inc. stock benefit from upcoming earnings reports2025 Fundamental Recap & Stock Portfolio Risk Management - Улправда
Cyclerion Therapeutics (NASDAQ:CYCN) Shares Down 0.7% – Should You Sell? - Defense World
Cyclerion Therapeutics Earnings Notes - Trefis
Can Cyclerion Therapeutics Inc. stock sustain institutional interestTrade Performance Summary & Safe Swing Trade Setups - Newser
Does Cyclerion Therapeutics Inc. stock trade at a discount to peersWeekly Loss Report & Verified Momentum Watchlists - Newser
How currency fluctuations impact Cyclerion Therapeutics Inc. stockJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - Newser
Cyclerion Therapeutics (CYCN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Cyclerion Therapeutics Inc. stock attractive for growth ETFsPortfolio Risk Report & Free Long-Term Investment Growth Plans - Newser
Cyclerion Receives Milestone Payment from Akebia - TipRanks
Cyclerion Therapeutics Announces Milestone Payment from Akebia - TradingView — Track All Markets
Akebia Therapeutics, Inc. Initiates Phase 2 Clinical Trials for the Treatment of Focused Segmental Glomerulosclerosis Using Praliciguat - marketscreener.com
Cyclerion Therapeutics, Inc. Announces Revision in Its Stock Evaluation Amid Financial Trends - Markets Mojo
Cyclerion Therapeutics Inc (CYCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
자본화:
|
볼륨(24시간):